Beryl Drugs Ltd Stock Price Today (NSE: BERLDRG)
Fundamental Score
Beryl Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Beryl Drugs Ltd share price today is ₹23.77, down 0.54% on NSE/BSE as of 22 September 2026. Beryl Drugs Ltd (BERLDRG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹12.06 (Cr). The 52-week high for BERLDRG share price is ₹27.60 and the 52-week low is ₹15.92. At a P/E ratio of 19.17x, BERLDRG is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 4.43% and a debt-to-equity ratio of 0.25.
Beryl Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Beryl Drugs Ltd share price chart: 2.66% return over the past month. 52-week high ₹27.60, 52-week low ₹15.92.
Beryl Drugs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹24.16 | ₹24.16 | ₹22.62 | ₹23.90 | 1.51K (Cr) | |
| ₹23.90 | ₹23.90 | ₹22.30 | ₹23.69 | 905.00 (Cr) | |
| ₹23.16 | ₹24.77 | ₹23.16 | ₹23.21 | 697.00 (Cr) | |
| ₹21.01 | ₹25.00 | ₹21.01 | ₹24.36 | 1.54K (Cr) | |
| ₹24.32 | ₹24.99 | ₹22.60 | ₹23.24 | 1.59K (Cr) | |
| ₹22.03 | ₹24.32 | ₹22.03 | ₹23.99 | 837.00 (Cr) | |
| ₹24.30 | ₹25.40 | ₹23.52 | ₹24.12 | 3.04K (Cr) | |
| ₹24.71 | ₹25.00 | ₹23.57 | ₹24.77 | 2.16K (Cr) | |
| ₹24.99 | ₹25.99 | ₹23.54 | ₹24.71 | 4.60K (Cr) | |
| ₹22.60 | ₹25.19 | ₹22.60 | ₹24.95 | 2.69K (Cr) |
Beryl Drugs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹24.00 | ₹26.50 | ₹21.01 | ₹23.90 | -0.42% | |
| ₹20.99 | ₹26.68 | ₹20.85 | ₹22.26 | +6.05% | |
| ₹22.05 | ₹25.03 | ₹20.00 | ₹20.25 | -8.16% | |
| ₹21.86 | ₹25.30 | ₹19.80 | ₹22.05 | +0.87% | |
| ₹20.86 | ₹22.89 | ₹19.01 | ₹20.84 | -0.10% | |
| ₹18.05 | ₹27.09 | ₹18.05 | ₹21.80 | +20.78% | |
| ₹20.69 | ₹22.34 | ₹15.92 | ₹19.28 | -6.81% | |
| ₹22.50 | ₹23.00 | ₹19.55 | ₹20.19 | -10.27% | |
| ₹23.47 | ₹23.95 | ₹21.01 | ₹21.99 | -6.31% | |
| ₹22.75 | ₹24.00 | ₹21.00 | ₹23.40 | +2.86% | |
| ₹23.50 | ₹24.75 | ₹20.50 | ₹22.71 | -3.36% | |
| ₹22.24 | ₹27.60 | ₹21.85 | ₹24.03 | +8.05% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Beryl Drugs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Beryl Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BERLDRG across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Attractive Valuation (P/E: 19.17 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (942.65%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (52.26%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (44.04% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (44.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 2.10)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (4.43%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.42%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Low Promoter Commitment (27.82%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Beryl Drugs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Beryl Drugs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Beryl Drugs LtdBeryl Drugs Ltd...Selected✓ BERLDRG • 524606 | 40/100 | ₹23.77₹24 | ₹12.06₹12.06 | 19.17Average 19.2 Average | 4.43%Poor 4.43% Poor | 8.42%Poor 8.42% Poor | 0.25Excellent 0.2 Excellent | 44.04%Excellent 44.04% Excellent | 6.60%Good 6.60% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1869.10₹1869 | ₹448453.16₹448453.16 | 37.09Average 37.1 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9460.50₹9461 | ₹250703.25₹250703.25 | 85.84Average 85.8 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4942.00₹4942 | ₹167266.93₹167266.93 | 78.95Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1130.60₹1131 | ₹112833.88₹112833.88 | 25.20Average 25.2 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.70₹1371 | ₹110732.00₹110732.00 | 32.84Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1929.70₹1930 | ₹104252.04₹104252.04 | 95.25Average 95.2 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.90₹1676 | ₹96431.29₹96431.29 | 26.19Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2096.80₹2097 | ₹95876.18₹95876.18 | 17.33Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.40₹1145 | ₹95640.90₹95640.90 | 29.60Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2263.00₹2263 | ₹93461.90₹93461.90 | 45.73Average 45.7 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price448453.16 Cr
- Divi's Laboratories Limited share price250703.25 Cr
- Torrent Pharmaceuticals Limited share price167266.93 Cr
- Zydus Lifesciences Limited share price112833.88 Cr
- Cipla Limited share price110732.00 Cr
Beryl Drugs Ltd PE Ratio History
Historical price-to-earnings ratio for BERLDRG — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.52 | ₹36.15 | 23.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Beryl Drugs Ltd Quarterly Performance
Latest quarterly metrics for BERLDRG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
52.26%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
942.65%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.60%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
44.04%
Compounded annual net profit growth over 5 years
Beryl Drugs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BERLDRG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Beryl Drugs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Beryl Drugs Ltd (BERLDRG) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Beryl Drugs Ltd
About BERLDRG (Beryl Drugs Ltd)
Beryl Drugs Ltd is a dynamic pharmaceutical entity rooted in the heart of India, dedicated to the development, production, and distribution of a diverse range of pharmaceutical sol...utions. Driven by a commitment to improving healthcare outcomes, the company meticulously crafts both branded and generic formulations, ensuring access to essential medicines for a wide spectrum of patients. Beyond traditional pills and tablets, Beryl Drugs specializes in sophisticated delivery systems including intravenous fluids and small volume injectables in both liquid and lyophilized forms. This comprehensive approach extends to specialized areas such as ophthalmic and otic solutions, alongside a dedicated line of veterinary products, solidifying its position as a versatile player in the pharmaceutical landscape. At the core of Beryl Drugs lies a robust infrastructure encompassing cutting-edge research and development capabilities. This investment in innovation fuels the creation of novel drug formulations and delivery methods, ensuring the company remains at the forefront of pharmaceutical advancements. Supplementing its in-house production, Beryl Drugs also provides contract manufacturing services, leveraging its state-of-the-art facilities and expertise to support other pharmaceutical companies. Stringent quality control measures permeate every stage of production, guaranteeing the safety and efficacy of all products bearing the Beryl Drugs name. Furthermore, the company actively pursues export opportunities, expanding its reach and contributing to global healthcare access. Established in 1993 and headquartered in the bustling city of Indore, Beryl Drugs Ltd has steadily grown to become a respected name in the Indian pharmaceutical industry. The company's success is built upon a foundation of ethical business practices, a skilled workforce, and a steadfast dedication to meeting the evolving needs of the healthcare sector. Through continuous investment in research, technology, and talent, Beryl Drugs remains poised to further its mission of providing high-quality, affordable medicines to improve the lives of people and animals, both domestically and internationally. Its long-standing presence in the market reflects its reliability and commitment to sustained growth and innovation.
Company Details
Key Leadership
BERLDRG Share Price: Frequently Asked Questions
What is the current share price of Beryl Drugs Ltd?
Beryl Drugs Ltd (BERLDRG) trades at ₹23.77 on NSE and BSE. Market cap ₹12.06 (Cr). Educational data only.
What is the P/E ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd has a P/E of 19.17x vs industry average 34.89x.
What is the Bull Run score for Beryl Drugs Ltd?
Beryl Drugs Ltd has a Bull Run score of 40/100 based on 25+ financial parameters.
Does Beryl Drugs Ltd pay dividends?
Beryl Drugs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Beryl Drugs Ltd?
Beryl Drugs Ltd has ROE of 4.43%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd has debt-to-equity of 0.25.
Is Beryl Drugs Ltd a good investment?
Bull Run gives Beryl Drugs Ltd a score of 40/100. This is not investment advice — consult a SEBI-registered advisor.